Development asset linked to HRA Pharma in public FDA and regional records.
pharma · Retinitis Pigmentosa · Dyslipidaemia
HRA Pharma
Laboratoire HRA Pharma
HRA Pharma drug portfolio — 17 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
CHATILLON, USA HQ
121 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- CHATILLON, USA
- Employees
- 121
- Programs
- 11
- Drugs
- 17
- Patents
- 0
HRA Pharma pipeline
Portfolio lens on 17 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
HRA Pharma drug portfolio — 17 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Mechanism: Surfactant agent.
- Mechanism
- Surfactant agent
-
Development asset linked to HRA Pharma in public FDA and regional records.
-
Development asset linked to HRA Pharma in public FDA and regional records.
-
ciclosporin
Sensory organs (S01)Sensory organs (S01) compound in HRA Pharma's portfolio. Molecular target: Peptidyl-prolyl cis-trans isomerase A.
- Target
- Peptidyl-prolyl cis-trans isomerase A
- Mechanism
- Cyclophilin A modulator
-
US regulatory status: approved. Molecular target: Vitamin D3 receptor.
- Target
- Vitamin D3 receptor
- Mechanism
- Vitamin D receptor agonist
-
fenofibrate
Cardiovascular system (C10)US regulatory status: approved. Molecular target: Peroxisome proliferator-activated receptor alpha.
- Target
- Peroxisome proliferator-activated receptor alpha
- Mechanism
- Peroxisome proliferator-activated receptor alpha agonist
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
Development asset linked to HRA Pharma in public FDA and regional records.
-
human coagulation factor viii / human von willebrand factor
Blood and blood forming organs (B02)Blood and blood forming organs (B02) compound in HRA Pharma's portfolio.
-
Development asset linked to HRA Pharma in public FDA and regional records.
-
Development asset linked to HRA Pharma in public FDA and regional records.
-
Development asset linked to HRA Pharma in public FDA and regional records.
-
Development asset linked to HRA Pharma in public FDA and regional records.
-
Development asset linked to HRA Pharma in public FDA and regional records.
-
Development asset linked to HRA Pharma in public FDA and regional records.
-
Development asset linked to HRA Pharma in public FDA and regional records.